Applied Filters
Takeda sues Mylan over gout generic
Takeda has sued Mylan for patent infringement and breach of a licencing agreement over Takeda’s Colcrys drug.
Generic drugmaker to pay $3m antitrust fine
New Jersey-based generic drugmaker Rising Pharmaceuticals has admitted to conspiring to fix prices and allocate customers for a generic hypertension drug.
LSPN Europe: understand our business models, say in-house lawyers
The best lawyers acting for life sciences companies make sure they fully understand their clients’ business models, said in-house counsel at Life Sciences Patent Network 2019.
LSPN Europe: new challenges for drug patent owners in Russia
Russian drug patent owners are being forced to come up with novel solutions to combat generic manufacturers trying to clear the way for competitor medicines.
Drop prices or lose patent rights, say White House hopefuls
US presidential candidates Bernie Sanders and Cory Booker have tabled a bill that would force drug companies to adhere to government-set prices-or risk losing patent exclusivity.
Russian government approves compulsory drug licensing bill
The Russian government has endorsed legislation that would allow it to employ compulsory drug licensing in emergencies.
Chinese state-owned chemical firm in fungicide patent suit
A Chinese state-owned chemical firm is suing US crop protection products company Atticus for patent infringement.
Novartis acquires Japanese generics business in €400m deal
Novartis has agreed to buy the Japanese business of South African generics manufacturer Aspen Pharmacare for a potential €400 million.
Pfizer and Sun settle Bosulif dispute
Pfizer and Indian drugmaker Sun Pharmaceuticals have agreed to settle patent litigation over a generic version of Pfizer’s leukaemia drug, Bosulif.
Takeda sells generics portfolio to Stada for $660m
German pharmaceutical company Stada Arzneimittel has acquired a portfolio of products from Takeda for $660 million.
